Mannin is a Canadian-based biotechnology company, with a newly formed subsidiary company in Germany, Mannin GmbH. Mannin’s mission is to “Drive innovation in life sciences to make a difference in healthcare globally”. Our team is focused on the discovery, research, development and commercialization of therapeutics for vascular diseases using a novel mechanism of action targeting the Tie2 (TEK) receptor tyrosine kinase. Mannin’s investment in its Tie2-based research platform has resulted in a diverse pipeline of new drugs and therapeutics, to treat a wide spectrum of vascular-related diseases.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
MAN-01 small molecule for Glaucoma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):